A Study for Japanese Participants With Rheumatoid Arthritis (RA)
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of multiple doses of LY2127399
(tabalumab) in Japanese participants with RA. The study consists of a 20-week treatment
period. All participants will be followed for up to 12 weeks after the last study drug
administration.